Contact

Echo-T

iPSC-derived T cell manufacturing platform supporting diverse immune cell therapy development needs

Echo-T provides a pre-established platform to support the development and GMP manufacturing of iPSC-derived T-cell therapies, from concept to clinic.

Start a conversation

[Add section intro copy]

Cell types

  • CD8
  • CD4
  • CD4/8 DP
  • NKT
  • Treg

Platform strengths

  • Differentiation protocol
  • Industrialized
  • Scalable
  • Feeder-free
  • Chemically defined

CDMO support

  • Tech transfer
  • Process & Analytical Development
  • Cell Line Development
  • Clinical Manufacturing & QC testing

Why iPSCs offer you a different path to control, consistency, and scale

Donor-derived cell therapy manufacturing — whether autologous or healthy-donor derived — is constrained by variability in starting material, limited scalability, and reduced control over downstream product design. iPSC-derived manufacturing changes that model by starting from a renewable, engineerable cell bank that supports process standardization, defined cell outputs, and industrialized scale-up.

How the approaches compare
iPSC-Derived Allogeneic
Healthy-Donor Allogeneic
Autologous
Source
Single, renewable iPSC cell banks
Primary cells from healthy donors
Patient's own cells
Scalability
n/a
Cost per dose
Consistency
Safety / Quality
Engineering potential
Ability to make cell type of choice
Only iPSC-derived allogeneic therapies unlock the scale, reliability, and cost-efficiency to deliver the full promise of cell therapy.

For developers, iPSCs shift the manufacturing model from donor-constrained operations toward a more standardized, engineerable, and scalable platform approach.

Echo-T applies this iPSC-based manufacturing logic to T-cell therapy development through an industrialized, CMC-integrated platform designed to support controlled development, GMP manufacturing, and long-term scale-up.

An industrialized process for iPSC-derived T-cell manufacturing

Echo-T follows a controlled manufacturing workflow organized into defined unit operations, from iPSC amplification to final drug product. Built for scalable GMP production, the platform combines feeder-free, chemically defined processing with stirred-tank bioreactors and in-process control across key stages.

iPSC Amplification
UOP 1
iPSC Amplification
Aggregate Generation
UOP 2
Aggregate Generation
In-Process Control
HSC Release Cryopreservation step
UOP 3
HSC Release
In-Process Control
T Activation & Differentiation
UOP 4
T Activation & Differentiation
T Expansion
UOP 5
T Expansion
In-Process Control
Automated Fill & Finish Cryopreservation step
UOP 6
Automated Fill & Finish
In-Process Control
Drug Product Release Cryopreservation step
Drug Product Release
  • Defined unit operations
  • Feeder-free, chemically defined process
  • No scale-limiting cell sorting steps
  • Stirred-tank bioreactors
  • In-process control

CDMO services for T-cell therapy programs

From development to GMP manufacturing, Cellistic supports the advancement of iPSC-derived T-cell therapies.

  • Process and analytical development
  • Manufacturing scale-up
  • GMP clinical manufacturing
  • Drug product and fill & finish
Explore our CDMO services

Platform outputs

Cellistic has developed the Echo-T GMP manufacturing platform to fully unlock the potential of allogeneic T-cells.

α/β T cells

Using a single master iPSC line, Echo-T produces CD4 and CD8 T cells at scale in a xeno-free medium. The cells carry no graft-versus-host disease risk, do not lose potency through over-activation during culture, and display functionality similar to primary T-cells — answering the manufacturing challenges currently preventing the widespread use of these therapies.

Poster downloadComing soon
α/β T cells data
α/β T cells data
15+
Years' experience in advancing iPSC science
32,000
Square feet of GMP manufacturing space
100L
Scale we achieve in stirred-tank bioreactors

Built on Cellistic's Echo platform expertise

Echo-T is part of Cellistic's Echo platform family for iPSC differentiation and scalable GMP manufacturing. The platform supports controlled development, clinically relevant manufacturing strategies, and reproducible scale-up across cell therapy programs. It integrates Cellistic's 15+ years of experience in cell therapy and batch release with access to a dedicated GMP manufacturing facility for iPSC-derived cell therapies in Belgium, Europe.

Explore Cellistic's GMP facility

What can Cellistic's Echo-T platform do for you?

Tell us about your T-cell therapy program and a member of our team will be in touch to explore how Echo-T can support your development and GMP manufacturing.